Moderna, Merck mRNA cancer vaccine prevents melanoma from returning
An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday. The positive results mean a potentially life-extending treatment is one step closer to being available on the market. They also herald a significant and…
The Hill
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from The Hill.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
The Hill (thehill.com), a Tier B publisher, filed this report on . CurrentWire published this page 1 minute later, on .
Signal breakdown
CurrentWire ranked this story 61.3 of 100 in the snapshot this page was rendered from.
- Freshness
- 31.8 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 8 of 10
- Velocity
- 0 of 5
Strongest signal: freshness, 31.8 of 35. How each signal is calculated.
Filed under Health · International · News.
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.